Article Details

Fate Therapeutics (FATE) Downgraded to Market Perform at UBS Group

Retrieved on: 2018-03-06 22:48:45

Tags for this article:

Click the tags to see associated articles and topics

Fate Therapeutics (FATE) Downgraded to Market Perform at UBS Group. View article details on hiswai:

Excerpt

<div>Finally, <b>Millennium Management</b> LLC increased its position in shares of Fate Therapeutics by 873.6% during the 4th quarter. <b>Millennium Management</b> LLC now owns 338,799 shares of the biopharmaceutical company's stock valued at $2,070,000 after purchasing an additional 303,999 shares during ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo